The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa

• Published in: Clinical neuropharmacology Vol. 25; no. 1; p. 21
• Main Authors: Rampello, Liborio, Chiechio, Santina, Raffaele, Rocco, Vecchio, Ignazio, Nicoletti, Francesco
• Format: Journal Article
• Language: English
• Published: United States 01.01.2002
• Subjects: Affect - drug effects; Antiparkinson Agents - therapeutic use; Carbidopa - therapeutic use; Citalopram - pharmacology; Citalopram - therapeutic use; Depression - complications; Depression - drug therapy; Dopamine Agents - therapeutic use; Drug Combinations; Female; Humans; Hypokinesia - drug therapy; Hypokinesia - etiology; Hypokinesia - psychology; Levodopa - therapeutic use; Male; Middle Aged; Parkinson Disease - complications; Parkinson Disease - drug therapy; Parkinson Disease - psychology; Psychiatric Status Rating Scales; Psychomotor Performance - drug effects; Serotonin Uptake Inhibitors - pharmacology; Serotonin Uptake Inhibitors - therapeutic use

Idiopathic Parkinson's disease (IPD) is characterized by motor signs such as akinesia, rigidity, and often tremor at rest. In addition to these symptoms, depression is a common finding affecting 40% of patients with IPD. This study evaluates the effect of the selective serotonin reuptake inhibi...